Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 6/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 6/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 6/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 10/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 10/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2199324 | 0.93 | MAPK13 (0.49) | MAPK13MAPK12MAPK11MAPK14ADRB2 | |
| SCHEMBL2198313 | 0.91 | MAPK13 (0.38) | MAPK13MAPK12MAPK11MAPK14ADRB2 | |
| SCHEMBL2196282 | 0.90 | MAPK13 (0.40) | MAPK13MAPK12MAPK11MAPK14MEN1 | |
| SCHEMBL2198346 | 0.88 | MAPK13 (0.45) | MAPK13MAPK12MAPK11MAPK14MEN1 | |
| SCHEMBL2198441 | 0.87 | MAPK1 (0.40) | MAPK13MAPK12MAPK11MAPK14ADRB2 | |
| SCHEMBL2199249 | 0.86 | MAPK13 (0.49) | MAPK13MAPK12MAPK11MAPK14MEN1 | |
| SCHEMBL12424062 | 0.86 | MAPK13 (0.56) | MAPK13MAPK12MAPK11MAPK14MEN1 | |
| SCHEMBL12424162 | 0.84 | MAPK13 (0.46) | MAPK13MAPK12MAPK11MAPK14MEN1 | |
| SCHEMBL2200151 | 0.83 | MAPK13 (0.55) | MAPK13MAPK12MAPK11MAPK14MEN1 | |
| SCHEMBL2196202 | 0.82 | MAPK13 (0.45) | MAPK13MAPK12MAPK11MAPK14ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2006528597-A | — | — | 2006-12-21 | — | — | JP | claimed |
| US-20060166990-A1 | Novel aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2006-07-27 | — | — | US | claimed |
| EP-1658263-A1 | NOVEL AMINOBENZOPHENONE COMPOUNDS | Leo Pharma A/S (DK) | 2006-05-24 | — | — | EP | claimed |
| WO-2005009940-A1 | NOVEL AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA A/S (DK) | 2005-02-03 | — | — | WO | claimed |
| US-7977387-B2 | Aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2011-07-12 | — | — | US | disclosed |
| US-7977387-B2 | Aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2011-07-12 | — | — | US | disclosed |
| US-7977387-B2 | Aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2011-07-12 | — | — | US | disclosed |
| US-20060166990-A1 | Novel aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2006-07-27 | — | — | US | disclosed |
| EP-1658263-A1 | NOVEL AMINOBENZOPHENONE COMPOUNDS | Leo Pharma A/S (DK) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005009940-A1 | NOVEL AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA A/S (DK) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166990-A1 | Novel aminobenzophenone compounds | NFKBIA, UACA, ALDH7A1 | MAPK13 1063/4885MAPK12 955/4885MAPK11 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.